Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Randomization tests as alternative analysis methods for behavior-analytic data.

Craig AR, Fisher WW.

J Exp Anal Behav. 2019 Feb 1. doi: 10.1002/jeab.500. [Epub ahead of print]

PMID:
30706944
2.

Baseline reinforcement rate and resurgence of destructive behavior.

Fisher WW, Saini V, Greer BD, Sullivan WE, Roane HS, Fuhrman AM, Craig AR, Kimball RT.

J Exp Anal Behav. 2019 Jan;111(1):75-93. doi: 10.1002/jeab.488. Epub 2018 Nov 29.

3.

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia.

Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Pigneux A, Horst HA, Récher C, Klimek VM, Cortes JE, Carella AM, Egyed M, Krug U, Fox JA, Craig AR, Ward R, Smith JA, Acton G, Kantarjian HM, Stuart RK.

Haematologica. 2018 Nov;103(11):e514-e518. doi: 10.3324/haematol.2018.191361. Epub 2018 May 24. No abstract available.

4.

Delivering alternative reinforcement in a distinct context reduces its counter-therapeutic effects on relapse.

Craig AR, Cunningham PJ, Sweeney MM, Shahan TA, Nevin JA.

J Exp Anal Behav. 2018 May;109(3):492-505. doi: 10.1002/jeab.431. Epub 2018 Apr 23.

PMID:
29683191
5.

Aging and anatomical variations in lung tissue stiffness.

Sicard D, Haak AJ, Choi KM, Craig AR, Fredenburgh LE, Tschumperlin DJ.

Am J Physiol Lung Cell Mol Physiol. 2018 Jun 1;314(6):L946-L955. doi: 10.1152/ajplung.00415.2017. Epub 2018 Feb 22.

PMID:
29469613
6.

On the predictive validity of behavioral momentum theory for mitigating resurgence of problem behavior.

Fisher WW, Greer BD, Craig AR, Retzlaff BJ, Fuhrman AM, Lichtblau KR, Saini V.

J Exp Anal Behav. 2018 Jan;109(1):281-290. doi: 10.1002/jeab.303.

7.

Greater reinforcement rate during training increases spontaneous recovery.

Thrailkill EA, Kimball RT, Kelley ME, Craig AR, Podlesnik CA.

J Exp Anal Behav. 2018 Jan;109(1):238-252. doi: 10.1002/jeab.307. Epub 2018 Jan 4.

PMID:
29314021
8.

Multiple schedules, off-baseline reinforcement shifts, and resistance to extinction.

Craig AR, Shahan TA.

J Exp Anal Behav. 2018 Jan;109(1):148-163. doi: 10.1002/jeab.300. Epub 2018 Jan 2.

PMID:
29293265
9.

Longer treatment with alternative non-drug reinforcement fails to reduce resurgence of cocaine or alcohol seeking in rats.

Nall RW, Craig AR, Browning KO, Shahan TA.

Behav Brain Res. 2018 Apr 2;341:54-62. doi: 10.1016/j.bbr.2017.12.020. Epub 2017 Dec 16.

PMID:
29258811
10.

Stimuli previously associated with reinforcement mitigate resurgence.

Craig AR, Browning KO, Shahan TA.

J Exp Anal Behav. 2017 Sep;108(2):139-150. doi: 10.1002/jeab.278. Epub 2017 Aug 29.

PMID:
28850670
11.

Quantitative models of persistence and relapse from the perspective of behavioral momentum theory: Fits and misfits.

Nevin JA, Craig AR, Cunningham PJ, Podlesnik CA, Shahan TA, Sweeney MM.

Behav Processes. 2017 Aug;141(Pt 1):92-99. doi: 10.1016/j.beproc.2017.04.016. Epub 2017 Apr 29. Review.

12.

Resurgence and alternative-reinforcer magnitude.

Craig AR, Browning KO, Nall RW, Marshall CM, Shahan TA.

J Exp Anal Behav. 2017 Mar;107(2):218-233. doi: 10.1002/jeab.245. Epub 2017 Feb 14.

13.

Resurgence as Choice.

Shahan TA, Craig AR.

Behav Processes. 2017 Aug;141(Pt 1):100-127. doi: 10.1016/j.beproc.2016.10.006. Epub 2016 Oct 26. Review.

14.

Effects of signaled and unsignaled alternative reinforcement on persistence and relapse in children and pigeons.

Nevin JA, Mace FC, DeLeon IG, Shahan TA, Shamlian KD, Lit K, Sheehan T, Frank-Crawford MA, Trauschke SL, Sweeney MM, Tarver DR, Craig AR.

J Exp Anal Behav. 2016 Jul;106(1):34-57. doi: 10.1002/jeab.213. Epub 2016 Jun 10.

15.

Behavioral momentum theory fails to account for the effects of reinforcement rate on resurgence.

Craig AR, Shahan TA.

J Exp Anal Behav. 2016 May;105(3):375-92. doi: 10.1002/jeab.207.

16.

Higher rate alternative non-drug reinforcement produces faster suppression of cocaine seeking but more resurgence when removed.

Craig AR, Nall RW, Madden GJ, Shahan TA.

Behav Brain Res. 2016 Jun 1;306:48-51. doi: 10.1016/j.bbr.2016.03.026. Epub 2016 Mar 14.

17.

Experience with dynamic reinforcement rates decreases resistance to extinction.

Craig AR, Shahan TA.

J Exp Anal Behav. 2016 Mar;105(2):291-306. doi: 10.1002/jeab.196. Epub 2016 Jan 27.

PMID:
26813330
18.

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.

Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst HA, Recher C, Klimek VM, Cortes J, Roboz GJ, Odenike O, Thomas X, Havelange V, Maertens J, Derigs HG, Heuser M, Damon L, Powell BL, Gaidano G, Carella AM, Wei A, Hogge D, Craig AR, Fox JA, Ward R, Smith JA, Acton G, Mehta C, Stuart RK, Kantarjian HM.

Lancet Oncol. 2015 Sep;16(9):1025-1036. doi: 10.1016/S1470-2045(15)00201-6. Epub 2015 Jul 30.

19.

Evaluating the influence of perceived pain control on patient satisfaction in a hospital setting.

Craig AR, Otani K, Herrmann PA.

Hosp Top. 2015 Jan-Mar;93(1):1-8. doi: 10.1080/00185868.2015.1012926.

PMID:
25839349
20.

Behavioral momentum and accumulation of mass in multiple schedules.

Craig AR, Cunningham PJ, Shahan TA.

J Exp Anal Behav. 2015 May;103(3):437-49. doi: 10.1002/jeab.145. Epub 2015 Mar 18.

21.

Resurgence of sucrose and cocaine seeking in free-feeding rats.

Shahan TA, Craig AR, Sweeney MM.

Behav Brain Res. 2015 Feb 15;279:47-51. doi: 10.1016/j.bbr.2014.10.048. Epub 2014 Nov 15.

22.

A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.

Lancet JE, Roboz GJ, Cripe LD, Michelson GC, Fox JA, Leavitt RD, Chen T, Hawtin R, Craig AR, Ravandi F, Maris MB, Stuart RK, Karp JE.

Haematologica. 2015 Feb;100(2):231-7. doi: 10.3324/haematol.2014.114769. Epub 2014 Nov 7.

23.

Do the adjusting-delay and increasing-delay tasks measure the same construct: delay discounting?

Craig AR, Maxfield AD, Stein JS, Renda CR, Madden GJ.

Behav Pharmacol. 2014 Aug;25(4):306-15. doi: 10.1097/FBP.0000000000000055.

24.

Pausing as an operant: choice and discriminated responding.

Craig AR, Lattal KA, Hall EG.

J Exp Anal Behav. 2014 Mar;101(2):230-45. doi: 10.1002/jeab.73. Epub 2014 Jan 16.

PMID:
24436113
25.

Temporal contingency.

Gallistel CR, Craig AR, Shahan TA.

Behav Processes. 2014 Jan;101:89-96. doi: 10.1016/j.beproc.2013.08.012. Epub 2013 Aug 29. Review.

26.

Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors.

Cortes J, Digumarti R, Parikh PM, Wetzler M, Lipton JH, Hochhaus A, Craig AR, Benichou AC, Nicolini FE, Kantarjian HM; Omacetaxine 203 Study Group.

Am J Hematol. 2013 May;88(5):350-4. doi: 10.1002/ajh.23408. Epub 2013 Mar 7.

27.

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.

Cortes J, Lipton JH, Rea D, Digumarti R, Chuah C, Nanda N, Benichou AC, Craig AR, Michallet M, Nicolini FE, Kantarjian H; Omacetaxine 202 Study Group.

Blood. 2012 Sep 27;120(13):2573-80. Epub 2012 Aug 15.

28.

Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells.

Allan EK, Holyoake TL, Craig AR, Jørgensen HG.

Leukemia. 2011 Jun;25(6):985-94. doi: 10.1038/leu.2011.55. Epub 2011 Apr 5.

PMID:
21468038
30.

Induction of complete remission using single agent clofarabine in a patient with primary refractory acute myeloblaste leukemia.

Douer D, Watkins K, Levine AM, Weiss JM, Marshall LC, Craig AR.

Leuk Lymphoma. 2003 Dec;44(12):2135-6.

PMID:
14959859
31.

Fluency outcomes following treatment for those who stutter.

Craig AR.

Percept Mot Skills. 2002 Jun;94(3 Pt 1):772-4.

PMID:
12081280
32.

The hidden cost of Membership examinations.

Lee TW, Craig AR, Ubhi T, Reece A.

Med Educ. 2002 Apr;36(4):395. No abstract available.

PMID:
11940192
33.

Recommendations for a mammography quality assurance program.

Craig AR, Heggie JC, McLean ID, Coakley KS, Nicoll JJ.

Australas Phys Eng Sci Med. 2001 Sep;24(3):107-31.

PMID:
11764394
34.

Positioning long lines: contrast versus plain radiography.

Reece A, Ubhi T, Craig AR, Newell SJ.

Arch Dis Child Fetal Neonatal Ed. 2001 Mar;84(2):F129-30.

35.

Automated homogeneous immunoassay for gentamicin on the dimension clinical chemistry system.

Wei TQ, Chu VP, Craig AR, Duffy JE, Obzansky DM, Kilgore D, Masulli IS, Sanders CM, Thompson JC.

Clin Chem. 1999 Mar;45(3):388-93.

36.

Immunizing against depression and anxiety after spinal cord injury.

Craig AR, Hancock K, Chang E, Dickson H.

Arch Phys Med Rehabil. 1998 Apr;79(4):375-7.

PMID:
9552101
37.

Kinetics and proposed mechanism of the reaction of an immunoinhibition, particle-enhanced immunoassay.

Thompson JC, Craig AR, Davey CL, Newman DJ, Lonsdale ML, Bucher WJ, Nagle PD, Price CP.

Clin Chem. 1997 Dec;43(12):2384-9.

38.

Long-term psychological outcomes in spinal cord injured persons: results of a controlled trial using cognitive behavior therapy.

Craig AR, Hancock K, Dickson H, Chang E.

Arch Phys Med Rehabil. 1997 Jan;78(1):33-8.

PMID:
9014954
39.

Development and validation of a particle-enhanced turbidimetric inhibition assay for urine albumin on the Dade aca analyzer.

Thakkar H, Newman DJ, Holownia P, Davey CL, Wang CC, Lloyd J, Craig AR, Price CP.

Clin Chem. 1997 Jan;43(1):109-13. Erratum in: Clin Chem 1997 Aug;43(8 Pt 1):1471.

40.

Oral anticoagulation nephrotic syndrome.

Craig AR, Brocklebank JT.

Arch Dis Child. 1996 Nov;75(5):462. No abstract available.

41.

Validation of a particle enhanced immunoturbidimetric assay for serum beta 2-microglobulin on the Dade aca.

Newman DJ, Kassai M, Craig AR, Gorman EG, Price CP.

Eur J Clin Chem Clin Biochem. 1996 Oct;34(10):861-5.

PMID:
8933113
42.

Mean glandular dose and the standard breast.

Thiele DL, Craig AR.

Australas Phys Eng Sci Med. 1996 Jun;19(2):94-6.

PMID:
8826714
43.

Results of a traditional acupuncture intervention for stuttering.

Craig AR, Kearns M.

J Speech Hear Res. 1995 Jun;38(3):572-8.

PMID:
7674649
44.
45.

The influence of spinal cord injury on coping styles and self-perceptions two years after the injury.

Craig AR, Hancock K, Chang E.

Aust N Z J Psychiatry. 1994 Jun;28(2):307-12.

PMID:
7993287
46.

Spinal cord injury: a search for determinants of depression two years after the event.

Craig AR, Hancock KM, Dickson HG.

Br J Clin Psychol. 1994 May;33 ( Pt 2):221-30.

PMID:
8038741
47.

Anxiety and depression over the first year of spinal cord injury: a longitudinal study.

Hancock KM, Craig AR, Dickson HG, Chang E, Martin J.

Paraplegia. 1993 Jun;31(6):349-57.

48.

Stabilization of turbidimetric immunoassay by covalent coupling of antibody to latex particles.

Thakkar H, Davey CL, Medcalf EA, Skingle L, Craig AR, Newman DJ, Price CP.

Clin Chem. 1991 Jul;37(7):1248-51.

49.

Following up on treated stutterers: studies of perceptions of fluency and job status.

Craig AR, Calver P.

J Speech Hear Res. 1991 Apr;34(2):279-84.

PMID:
2046352
50.

Psychological consequences of spinal injury: a review of the literature.

Craig AR, Hancock KM, Dickson H, Martin J, Chang E.

Aust N Z J Psychiatry. 1990 Sep;24(3):418-25. Review.

PMID:
2241726

Supplemental Content

Loading ...
Support Center